Artificial cerebrospinal fluid (aCSF; 145 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 1.2 mM CaCl2, 0.45 mM monobasic phosphate, 1.55 mM dibasic phosphate, pH 7.4) and high potassium aCSF (95 mM NaCl, 50 mM KCl, 1.0 mM MgCl2, 1.2 mM CaCl2, 0.45 mM monobasic phosphate, 1.55 mM dibasic phosphate, pH 7.4) was prepared weekly with components from Fisher Scientific (Pittsburgh, PA). Ro60-0175 and ketanserin were purchased from Tocris Bioscience (Bristol UK). The novel compounds, (−)-trans-4-phenyl-2-N,N-dimethylaminotetralin ((−)-trans- PAT), (−)-trans-4-(4′ [para]-chlorophenyl)-2-N,N-dimethylaminotetralin ((−)-trans-p-Cl-PAT), (−)- trans-4-cylcohexyl-2-N,N-dimethylaminotetralin ((−)-trans-CAT), and (−)-trans-4-(3′ [meta]-chlorphenyl)-6-methoxy-N,N-dimethyl-1,2,3,4-tetrahydronaphthalene-2-amine (m-Cl-6-OMe- PAT) were synthesized in the University of Florida Department of Medicinal Chemistry laboratories with details reported elsewhere (Booth et al., 2009 (link); Canal et al., 2013b (link); Morgan et al., 2013 (link); Vincek and Booth, 2009 (link)). All drugs were prepared in aCSF.